GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » Altman Z-Score

Fangzhou (HKSE:06086) Altman Z-Score : 1.85 (As of Mar. 14, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.62 is in distress zone. This implies bankruptcy possibility in the next two years.

Fangzhou has a Altman Z-Score of 1.85, indicating it is in Grey Zones. This implies that Fangzhou is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Fangzhou's Altman Z-Score or its related term are showing as below:

HKSE:06086' s Altman Z-Score Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.62
Current: 1.62

During the past 3 years, Fangzhou's highest Altman Z-Score was 1.62. The lowest was 0.00. And the median was 0.00.


Fangzhou Altman Z-Score Historical Data

The historical data trend for Fangzhou's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou Altman Z-Score Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23
Altman Z-Score
- - -

Fangzhou Semi-Annual Data
Dec21 Dec22 Dec23
Altman Z-Score - - -

Competitive Comparison of Fangzhou's Altman Z-Score

For the Pharmaceutical Retailers subindustry, Fangzhou's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fangzhou's Altman Z-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Fangzhou's Altman Z-Score falls into.



Fangzhou Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Fangzhou's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.028+1.4*-2.2267+3.3*-0.3742+0.6*2.6046+1.0*4.6691
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was HK$570 Mil.
Total Current Assets was HK$511 Mil.
Total Current Liabilities was HK$527 Mil.
Retained Earnings was HK$-1,270 Mil.
Pre-Tax Income was HK$-215 Mil.
Interest Expense was HK$-2 Mil.
Revenue was HK$2,663 Mil.
Market Cap (Today) was HK$6,902 Mil.
Total Liabilities was HK$2,650 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(511.182 - 527.138)/570.261
=-0.028

X2=Retained Earnings/Total Assets
=-1269.816/570.261
=-2.2267

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-215.158 - -1.794)/570.261
=-0.3742

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=6902.378/2650.041
=2.6046

X5=Revenue/Total Assets
=2662.595/570.261
=4.6691

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Fangzhou has a Altman Z-Score of 1.85 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Fangzhou  (HKSE:06086) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Fangzhou Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Fangzhou's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Asia Tech Holdings Limited 2201 Interest of corporation controlled by you
Vistra Trust (hong Kong) Limited 2301 Trustee
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines